			Home About us Contact

Optimal Balance (optimal + balance)

Distribution by Scientific Domains

Medical Sciences	33%
Business, Economics, Finance and Accounting	33%

Selected Abstracts

Prospects for therapeutic vaccination with glatiramer acetate for neurodegenerative diseases such as Alzheimer's disease

DRUG DEVELOPMENT RESEARCH, Issue 2 2002
Michal Schwartz
Abstract Neurodegenerative diseases, whatever their primary causes, are characterized by certain common features, one of which is their self-perpetuating nature. The ongoing progression of the disorder is due to the effects of destructive self-compounds, whose presence in the tissues is an outcome of the early phase of the disease and which gradually destroy remaining functional neurons. Studies in our laboratory have led to the recent formulation of a novel concept of protective autoimmunity as the body's mechanism of defense against these destructive self-compounds. This autoimmune response to central nervous system (CNS) insults is mediated by T-cells and presumably operates by activating and regulating local microglia and infiltrating macrophages (inflammatory response) to carry out their function of clearing destructive material from the tissue at risk. We suggest that a well-controlled autoimmunity counteracts and overcomes the destructive effects of the potentially harmful self-compounds, at the cost of some loss of tissue. An additional risk to the individual is the induction of an autoimmune disease, which is likely to occur if the autoimmune response is malfunctioning. An optimal balance of the various factors will lead to an outcome of maximal benefit at minimal cost to the tissue. A procedure for safely boosting the autoimmune response, by vaccination with a weak self-crossreactive antigen such as glatiramer acetate (also known as Cop-1) was found to protect rats from glutamate toxicity, a major mediator of the spread of damage and a well-known causative factor in neurodegenerative disorders. Cop-1, when administered according to a different regimen, is an FDA-approved drug for the treatment of multiple sclerosis. Different formulations of the same drug can therefore be used to treat two extreme manifestations of chronic degenerative diseases of the CNS. Drug Dev. Res. 56:143,149, 2002. © 2002 Wiley-Liss, Inc. [source]

The Takeover Directive: Is a Little Regulation Better Than No Regulation?

EUROPEAN LAW JOURNAL, Issue 2 2009
Blanaid Clarke
This article examines Directive 2004/25/EC on Takeover Bids through a regulatory lens in order to determine its effectiveness as a regulatory mechanism. A central regulatory problem for European legislators is to determine the optimal balance between harmonisation and diversity, and the directive reflects the balance which was struck. The article questions whether the resulting ,light regulatory touch' may have jeopardised the existing efficient self-regulatory regime which operates in the UK (the largest European takeover market), while simultaneously undermining the directive's goal of facilitating takeovers and yielding a level playing field. [source]

Designing merger agreements to ease merger integration

GLOBAL BUSINESS AND ORGANIZATIONAL EXCELLENCE, Issue 1 2008
Sascha L. Schmidt
Many mergers fail as a result of difficulties in the integration phase. Such problems can arise when the corporate strategy concept of the merged firm does not build in a meaningful way on the actual corporate strategies of the predecessor organizations. Primarily addressed to practitioners, this article introduces the framework of a "merger scan" that enables executives negotiating a deal to analyze whether alternative versions of the new corporate strategy strike an optimal balance between the desire for continuity and the need for strategic renewal. Applying this framework helps executives allocate sufficient time and attention to those integration aspects that involve breaking with the directions of the predecessor firms and thus require change. © 2008 Wiley Periodicals, Inc. [source]

Dose Range-Finding Studies With Frovatriptan in the Acute Treatment of Migraine

HEADACHE, Issue 2002
Alan Rapoport MD
Objective.,To determine the optimum dose of frovatriptan for the acute treatment of migraine. Background.,Frovatriptan is a new triptan developed for the acute treatment of migraine. The dose-response characteristics and safety of frovatriptan have been investigated across a broad range of doses from 0.5 to 40 mg. Design.,Two randomized, placebo-controlled, double-blind, parallel-group trials, with a total of 1453 patients, were performed to determine the optimal dose of the 5-HT1B/1D agonist, frovatriptan, for the acute treatment of migraine. The dose ranges studied were 2.5 to 40 mg in the high-dose study and 0.5 to 5 mg in the low-dose study. Results.,At 2 hours postdosing for initial moderate or severe headache (International Headache Society grades 2 or 3), there was an approximate two-fold difference in the proportion of patients taking frovatriptan doses of 2.5 to 40 mg with mild or no headache compared to placebo. Frovatriptan doses of 0.5 mg and 1 mg were not more effective than placebo at 2 hours postdose, and 2.5 mg was identified as the lowest effective dose for the relief of migraine and accompanying symptoms. Above 2.5 mg, no dose-response relationship was observed for any efficacy parameters. There was an increase in the incidence of adverse events from 10 mg and above, but the vast majority were rated as mild in severity and did not impact upon tolerability in a significant manner. Conclusions.,Frovatriptan was well tolerated throughout the dose range of 0.5 to 40 mg. The 2.5-mg dose confers the optimal balance of efficacy and tolerability for the acute treatment of migraine. [source]

Product Quality and the Optimal Structure of Commodity Taxes

JOURNAL OF PUBLIC ECONOMIC THEORY, Issue 4 2006
SOFIA DELIPALLA
The comparison between ad valorem and specific taxation is among the oldest issues in formal public finance and is important for policy in the European Union (EU) and elsewhere. This paper develops and articulates simple but very general elasticity rules that characterize the optimal balance between the two in a model of endogenous product quality. These rules temper the preference for ad valorem taxation that emerges from homogeneous product models, pointing to relatively heavy reliance on whichever form of taxation has the least effect on product quality. [source]

Discriminating tastes: self-selection of macronutrients in two populations of grasshoppers

PHYSIOLOGICAL ENTOMOLOGY, Issue 3 2008
DENNIS J. FIELDING
Abstract The capacity to self-select an optimal balance of macronutrients (protein and carbohydrate) is studied in two populations of Melanoplus sanguinipes F. (Orthoptera: Acrididae). One population derives from the subarctic (interior of Alaska) and the other from the temperate zone (Idaho, U.S.A.). Over the duration of the fourth and fifth stadia, Alaskan grasshoppers consistently self-select a diet centred on a 0.90 ratio of protein : carbohydrate, whereas protein and carbohydrate intake by the Idaho grasshoppers is contingent on the particular food choices presented to them. When restricted to imbalanced diets, the Alaskan grasshoppers develop more rapidly than the Idaho grasshoppers, regardless of diet composition. The Idaho grasshoppers also have a greater amount of lipid than the Alaskan grasshoppers across all diets. Performance measures (body mass, survival, developmental times) are more sensitive to dietary imbalances in the Alaskan grasshoppers than in the Idaho grasshoppers. When fed diets with low, but balanced, proportions of protein and carbohydrate, grasshoppers of both populations are able to increase consumption to compensate for the low concentration of nutrients. The results suggest that demographic responses of insects to changes in host plant quality, such as may result from climate change, may differ among populations within a species. [source]